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We conducted a prospective, open-label multicenter trial to
evaluate the efficacy and safety of treating children with
frequently relapsing nephrotic syndrome with cyclosporine.
Patients were randomly divided into two groups with both
initially receiving cyclosporine for 6 months to maintain a
whole-blood trough level between 80 and 100 ng/ml. Over
the next 18 months, the dose was adjusted to maintain a
slightly lower (60–80 ng/ml) trough level in Group A, while
Group B received a fixed dose of 2.5 mg/kg/day. The primary
end point was the rate of sustained remission with analysis
based on the intention-to-treat principle. After 2 years, the
rate of sustained remission was significantly higher while the
hazard ratio for relapse was significantly lower in Group A
as compared with Group B. Mild arteriolar hyalinosis of the
kidney was more frequently seen in Group A than in Group B,
but no patient was diagnosed with striped interstitial
fibrosis or tubular atrophy. We conclude that cyclosporine
given to maintain targeted trough levels is an effective
and relatively safe treatment for children with frequently
relapsing nephrotic syndrome.
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The establishment of effective and safe immunosuppressive
therapies other than corticosteroids is urgently required for
children with frequently relapsing nephrotic syndrome
(FRNS). Although corticosteroids remain the first-line
treatment for nephrotic syndrome and approximately 90%
of patients have remission during treatment, a substantial
proportion of these patients progress to FRNS.1–4 Cortico-
steroid-related toxicity may lead to serious problems in these
patients, such as growth failure, osteoporotic bone disease,
cataract and glaucoma, and adrenal suppression.
Cyclosporine (CyA) is an immunosuppressive drug that
has been used to sustain remission and decrease exposure to
corticosteroids in children with steroid-sensitive nephrotic
syndrome.5–20 Although CyA has been shown to be as
effective as other immunosuppressive drugs, such as
cyclophosphamide and chlorambucil, in children with FRNS
or steroid-dependent nephrotic syndrome, its general use
remains controversial because of potentially serious adverse
effects, including hypertension, infection, neurotoxicity, and
nephrotoxicity.2,5,6,12,21–24
The optimal dosage and duration of treatment with CyA
for these patients have yet to be determined. Short-term
(6-month) courses of CyA are associated with frequent
relapses of nephrotic syndrome just after the discontinuation
of treatment.11 Low-dose treatment with CyA for 18 months
has also produced discouraging results.10 On the other hand,
2 years of treatment with CyA in a dose producing a
trough level of 100 ng/ml caused chronic CyA-induced
nephrotoxicity in 7 of 13 patients.8 To better define the
optimal dosage and duration of treatment with CyA, we
conducted a prospective, randomized, open-label multicenter
trial to evaluate the efficacy and toxicity of a 2-year course
of treatment with CyA (Sandimmune; Novartis, Basel,
Switzerland) in children with FRNS.
RESULTS
Analysis set (data set)
Between January 1996 and January 2002, a total of 56
patients were registered at 23 centers and randomly assigned
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to treatment group (Group A, 29; Group B, 27). One patient
was later found to be ineligible, and another patient was lost
to follow-up and had no data available. These two patients
were excluded from all analyses. All 10 patients enrolled at
three particular centers received the regimen for Group A
regardless of the assigned treatment (three patients in Group
A and seven in Group B); the steering committee decided to
exclude these 10 patients from all analyses except for the
analysis of adverse events because these three centers were
considered to violate the guidelines for good clinical practice
in Japan. Therefore, this report is based on 44 patients in the
intention-to-treat analysis.
A flow diagram of the patients, summarizing the numbers
of patients assigned to treatment, followed up, and included
in analyses, is shown in Figure 1. Data from 3 of 17 patients
who discontinued the allocated treatment regimen were used
as censored observations in the survival analyses: 1 (Group B)
because of progression to steroid resistance and 2 because of
adverse events (Group A, 1 and Group B, 1).
Patient characteristics
The clinical characteristics of the patients were analyzed to
confirm whether major prognostic factors were balanced
between the treatment groups. The mean age of the patients
was 8.5 years in Group A and 8.9 years in Group B. The
demographic characteristics of the patients are shown in
Table 1. Before study entry, the number of relapses/year was
3.1 in Group A and 3.6 in Group B (Table 2a, P¼ 0.155). The
demographic characteristics of the 10 patients treated at the
three excluded centers are also shown in Table 2b.
As for concomitant medications, angiotensin-converting
enzyme inhibitors (lisinopril or enalapril) were used in four
patients in Group A and one patient in Group B. Calcium
channel blockers (nifedipine or amlodipine) were used in two
56 participants
56 randomized
29 allocated to regimen A 27 allocated to regimen B
1 lost contact with patient
1 did not meet eligibility criteria
3 from ineligible institutions
Discontinued interventions Discontinued interventions
6 progressed to FRNS 8 progressed to FRNS
1 progressed to SRNS1 adverse event
1 adverse event
24 analyzed
20 renal biopsies at month 24
20 analyzed
15 renal biopsies at month 24
7 from ineligible institutions
Excluded
Excluded
Figure 1 | Flow diagram of the patients. SRNS, steroid-resistant nephrotic syndrome; FRNS, frequently relapsing nephrotic syndrome.
Table 1 | Patient demographics
Group A (N=24) Group B (N=20)
Characteristics Level N (%) N (%)
Age at entry (years) 0 to o3 1 (4.2) 4 (20.0)
X3 to o6 6 (25.0) 3 (15.0)
X6 to o11 9 (37.5) 5 (25.0)
X11 8 (33.3) 8 (40.0)
Age at diagnosis (years) 0 to o3 3 (12.5) 5 (25.0)
X3 to o6 13 (54.1) 9 (45.0)
X6 to o11 4 (16.7) 3 (15.0)
X11 4 (16.7) 2 (10.0)
Missing 0 (0.0) 1 (5.0)
Sex Male 18 (75.0) 17 (85.0)
Female 6 (25.0) 3 (15.0)
Table 2a | Relapse rate before entry
Number of relapses before entry (per year)
Treatment N Missing Mean Median s.d. Min Max
Group A 24 1 3.1 3 1.02 2 5
Group B 20 1 3.6 3 1.22 2 6
Table 2b | Relapse rate before entry in 10 patients at the
three excluded institutions
Number of relapses before entry (per year)
Treatment N Missing Mean Median s.d. Min Max
Group A 3 1 3.0 3 1.41 2 4
Group B 7 2 3.6 3 0.89 3 5
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patients in group A and one patient in group B. No patient
was prescribed HMG-CoA reductase inhibitors (statins) in
either group.
CyA dosage and trough level
The mean dose of CyA required to maintain the whole-blood
trough level between 80 and 100 ng/ml during the first
6 months of treatment was 5.4 mg/kg/day in Group A and
4.7 mg/kg/day in Group B (P¼ 0.152). During the next
18 months in Group A, the mean dose of CyA required
to maintain a trough level between 60 and 80 ng/ml was
4.8 mg/kg/day (Table 3a). The distribution of the median
trough level of CyA during follow-up is shown according to
group in Table 3b. During the first 6 months of treatment
(the same in both groups), the median trough level of CyA
was between 60 and 100 ng/ml in more than 60% of the
patients in each group.
Sustained remission
The estimated relapse rate was 0.34 per year for Group A and
0.93 per year for Group B. The rate of patients with sustained
remission is shown according to group in Figure 2. At month
24, the estimated sustained remission rate was significantly
higher in Group A (50%) than in Group B (15%, P¼ 0.006).
The hazard ratio for relapse was 0.37 (95% CI: 0.18–0.79,
P¼ 0.01) in Group A as compared with Group B.
The sustained remission rate among patients without
relapse during the first 6 months is shown in Figure 3. At
month 24, the estimated sustained remission rate was 57% in
Group A and 25% in Group B (P¼ 0.060). The hazard ratio
for relapse was 0.43 (95% CI: 0.17–1.09, P¼ 0.075) in Group
A as compared with Group B.
Progression-free survival
The estimated rate of progression to FRNS was 0.14 per year
in Group A and 0.42 per year in Group B. As shown in
Figure 4, the progression (to FRNS)-free survival at month
24 was 75% in Group A and 56% in Group B (P¼ 0.16).
The hazard ratio for progression to FRNS was 0.48 (95% CI:
0.16–1.38, P¼ 0.17).
Progression-free survival among patients without progres-
sion to FRNS during the first 6 months is shown in Figure 5.
At month 24, the estimated progression-free survival was
78% in Group A and 59% in Group B (P¼ 0.13). The hazard
ratio for progression to FRNS was 0.43 (95% CI: 0.14–1.37,
P¼ 0.15).
Adverse events
Adverse events are summarized in Table 4. The incidence of
hypertension was 25% (6/24) in Group A and 10% (2/20) in
Table 3a | Dose of cyclosporine
CyA dose (mg/kg/day)
Time Treatment N Mean Median s.d. Min Max
Months 1–6 Group A 24 5.4 5.1 1.41 2.8 7.9
Group B 20 4.7 4.7 1.64 2.0 7.1
Months 7–24 Group A 23 4.8 4.7 1.03 2.9 7.1
Group B 19 2.5 2.5 — — —
CyA, cyclosporine.
Table 3b | Median trough level of cyclosporine
Group A Group B
Period Trough level of CyA (ng/ml) N (%) N (%)
Months 1–6 X40 to o60 1 (4.3) 3 (15.0)
X60 to o80 8 (34.8) 12 (60.0)
X80 to o100 8 (34.8) 3 (15.0)
X100 6 (26.1) 2 (10.0)
Months 7–24 o30 0 (0.0) 6 (37.4)
X30 to o40 0 (0.0) 5 (31.2)
X40 to o60 3 (13.6) 3 (18.8)
X60 to o80 13 (59.1) 1 (6.3)
X80 to o100 6 (27.3) 1 (6.3)
CyA, cyclosporine.
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Figure 2 | Proportion of patients with sustained remission among
all patients.
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Figure 3 | Proportion of patients with sustained remission among
patients who had no relapse for the first 6 months.
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Group B (P¼ 0.20). Transient elevation of serum creatinine
was observed in three patients (Group A, 2 and Group B, 1).
There was one severe adverse event. Ileus of unknown
origin developed at month 22 in a 10-year-old girl assigned to
Group A. This event was managed conservatively and
resulted in death; an autopsy was not performed. The other
noteworthy events were convulsions in one patient in Group
A and gastric discomfort in one patient in Group B. The
patient with convulsions had progression to FRNS before the
seizures occurred, but continued to receive Regimen A.
Therefore, a relation of treatment to the convulsions could
not be ruled out. In the patient with gastric discomfort,
symptoms subsided after the withdrawal of CyA. This adverse
event was, therefore, considered to be related to treatment.
Renal biopsies were performed in 35 patients (Group A,
20 and Group B, 15) at the end of the study. Mild arteriolar
hyalinosis was found in 4 (20%) of 20 patients undergoing
biopsy in Group A and 1 (6.7%) of 15 undergoing biopsy in
Group B; however, no patient had striped interstitial fibrosis
or tubular atrophy.
In the 10 patients at the excluded centers (all received
Regimen A), there were no severe adverse effects. Elevation of
alkaline phosphatase occurred in three patients, hyperurice-
mia in three, transient elevation of serum creatinine in one,
and hypertrichosis in one. At the end of the treatment, renal
biopsy was performed in four patients; none of these patients
had evidence of nephrotoxicity.
Growth failure
Before CyA treatment (at study entry), the mean s.d. score for
body height was 0.70 (95% CI: 1.17 to 0.23) in Group A
(n¼ 24) and 0.62 (95% CI: 1.23 to 0.02) in Group B
(n¼ 18). At the end of the study, the mean s.d. score for body
height was 0.10 (95% CI: 0.54 to 0.33) in Group A
(n¼ 23) and 0.07 (95% CI: 0.74 to 0.60) in Group B
(n¼ 18). There was no statistically significant difference
between the two groups. However, the s.d. score for height
increased significantly from the start to the end of the study
in both groups; Group A: þ 0.61 (n¼ 23; paired t-test,
P¼ 0.0001), Group B: þ 0.58 (n¼ 17, P¼ 0.0001).
DISCUSSION
We conducted a prospective, randomized, open-label multi-
center trial in children with FRNS to evaluate the efficacy and
safety of 2 years of treatment with CyA.
Our results were consistently in favor of Regimen A. CyA
treatment for 2 years in a dosage that maintained the trough
level between 80 and 100 ng/ml from study entry to month 6
and between 60 and 80 ng/ml from months 7 to 24
(Regimen A) was more effective in terms of the duration
of remission and reduction in the risk of progression to
FRNS than was CyA in a fixed dose of 2.5 mg/kg/day during
months 7–24 (Regimen B), the regimen approved by the
Ministry of Health, Labour and Welfare (MHLW) in Japan.
Although several retrospective studies have proposed each
of these regimens,19,25 to our knowledge this is the first
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Figure 4 | Progression (to FRNS)-free survival among all patients.
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Figure 5 | Progression-free survival among patients who did not
progress to FRNS during the first 6 months.
Table 4 | Adverse events
Group A
(N=24)
Group B
(N=20)
Incidence Incidence
Adverse events N (%) N (%)
Hypertension 6 (25.0) 2 (10.0)
Hypertrichosis 4 (16.7) 3 (15.0)
Gingival hypertrophy 2 (8.3) 4 (20.0)
Gastric pain 1 (4.2) 1 (5.0)
Headache 1 (4.2) 1 (5.0)
Ileus 1 (4.2) 0 (0.0)
Gastric discomfort 0 (0.0) 1 (5.0)
Malaise 1 (4.2) 0 (0.0)
Hypoesthesia 1 (4.2) 0 (0.0)
Psychiatric symptoms 0 (0.0) 1 (5.0)
Obesity 1 (4.2) 0 (0.0)
Convulsions 1 (4.2) 0 (0.0)
Elevation of ALP (41000 IU/l) 6 (25.0) 6 (30.0)
Elevation of urinary b2 MG (4500mg/l) 8 (33.3) 4 (20.0)
Hyperuricemia (48 mg per 100 ml) 5 (20.8) 3 (15.0)
Transient elevation of serum creatine 2 (8.3) 1 (5.0)
ALP, alkaline phosphatase; b2MG, b2 microglobulin.
1170 Kidney International (2008) 73, 1167–1173
o r i g i n a l a r t i c l e K Ishikura et al.: Cyclosporine in children with nephrotic syndrome
multicenter, prospective, randomized trial to assess the safety
and effectiveness of long-term treatment with CyA in
children with FRNS. Although statistically not significant,
similar results were obtained among patients without relapse
or progression to FRNS during the first 6 months of
treatment: Regimen A was superior to Regimen B with
respect to maintaining remission and reducing the risk of
progression to FRNS.
The management of nephrotic syndrome in children
depends to a large extent on the response to corticosteroids
and the frequency of relapses. Patients whose disease is
refractory to corticosteroids have a rather poor prognosis and
respond differently to CyA than patients with steroid-
sensitive disease.2,12,26 Most patients with steroid-sensitive
nephrotic syndrome have a good prognosis.1,27 In such
patients, adverse effects of therapy are a major concern that
may negatively affect the general condition and disease status
of patients. Some patients with FRNS have severe adverse
reactions to corticosteroids and may particularly benefit from
immunosuppressants with steroid-sparing effects.5,6,23
Cyclosporine is widely used to treat FRNS in children;
however, the optimal dosage and duration of treatment
remain controversial. Nephrotoxicity is the most important
adverse effect of CyA.12,22 Typical CyA-induced chronic
nephrotoxicity is characterized by arteriolopathy and striped
interstitial fibrosis with tubular atrophy.17,28 Hamahira et al.9
showed that arteriolopathy resolved 6–19 months after the
withdrawal of CyA, whereas interstitial fibrosis and tubular
atrophy did not. These findings suggested that the dose of
CyA should be carefully adjusted to avoid the development of
CyA-induced tubulointerstitial changes in children with
FRNS. One previous study showed that 2 years of treatment
with CyA in a dose that maintained the trough level at
100 ng/ml caused tubulointerstitial changes in 7 of 13
patients.8 Iijima et al.7 reported that the risk factors for
CyA-induced tubulointerstitial lesions included a duration of
treatment exceeding 24 months and the presence of heavy
proteinuria for more than 30 days during treatment. On
the other hand, several studies assessing the value of short-
term treatment with CyA demonstrated an insufficient
response.10,11,29,30 To better define the optimal dosage, we
compared the safety and effectiveness of two dosage regimens
given for 2 years. Regimen A was found to be an effective and,
as discussed below, relatively safe treatment for children with
FRNS.
We also evaluated the effect of CyA treatment on growth.
Growth failure is a particularly important problem for
children, with profound effects on their quality of life. The
mean s.d. score for height and the change from the baseline
value were evaluated in each group. Our results indicate that
CyA has a beneficial effect on growth: height approached the
mean value of Japanese healthy children after CyA treatment
in both groups. This result is consistent with the findings of a
meta-analysis of similar cohorts of patients.31 Improved
height is attributable to the decreased exposure to cortico-
steroids enabled by the administration of CyA.
In general, Regimen A appeared to be as well tolerated as
Regimen B in terms of safety. Frequent adverse events were
hypertension, hypertrichosis, elevation of serum alkaline
phosphatase levels (41000 IU/l), elevation of urinary
b2-microglobulin levels (4500 mg/l), and hyperuricemia
(48 mg per 100 ml). Mild nephrotoxicity associated with
mild arteriolar hyalinosis was found in four patients in
Group A and one in Group B. Among these adverse effects,
hypertension, elevation of urinary b2-microglobulin, and
nephrotoxicity were slightly but not significantly more
frequent in Group A. High trough levels may increase the
risk of these adverse events, and hypertension and nephro-
toxicity might have been related. Careful observation and
management of blood pressure and renal function are thus
required in patients who receive Regimen A. Fortunately, no
severe pathological changes of the kidney, such as interstitial
fibrosis and tubular atrophy, were detected in either group.
As stated above, the pathological changes of the kidney in our
series are expected to resolve with time. As for the death
associated with ileus in Group A, the precise cause is unclear
because an autopsy was not performed. To our knowledge,
however, a direct link between CyA and severe ileus has not
been reported previously; the development of ileus thus
appears to be an incidental finding.
Protocol violations are an important concern of the
present study. Seven patients at the three centers who were
assigned to Group B received the regimen for Group A
(Regimen A), that is, from month 7 onward the dose of CyA
was adjusted to maintain the trough level between 60 and
80 ng/ml, instead of using a fixed dose of 2.5 mg/kg. The
steering committee decided that additional patients would
not be enrolled at these centers. The reason for these
violations was that the physicians in charge at these three
centers had assumed that Regimen A was more effective than
Regimen B, irrespective of potential adverse effects. Thus, the
steering committee finally decided to exclude these ineligible
centers, and the 10 patients were excluded from all analyses
except for those of adverse effects. Because these protocol
violations were unrelated to disease severity and the disease
severity of the 10 excluded patients was similar to that of the
patients analyzed (Table 2a and b), comparability of the
treatment groups was considered to be maintained.
Another limitation is that all of our patients received
Sandimmune, the older formulation of CyA. Whether our
results can be extrapolated to patients who receive the newer
formulation of CyA, Neoral (Novartis), must be carefully
considered. Several studies have compared efficacy and safety
between Sandimmune and Neoral in children with nephrotic
syndrome16 and renal-transplant recipients.32–34 Neoral has
consistently been shown to be more effective, without
compromising safety. To confirm the efficacy and safety of
Neoral administered according to Regimen A, we are
currently conducting a multicenter prospective trial.
The trough level monitoring (C0) was used to titrate the
dosage of CyA in this trial. For the recipients of kidney
transplants, C2 monitoring (C2) has been shown to be a
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more superior strategy compared with C0 in the prevention
of acute rejection.35,36 Preliminary data obtained from the
ongoing trial of Neoral mentioned above indicate that C2 as
well as C0 correlate with clinical response. Thus, in Japan
another new multicenter clinical trial supported by the
MHLW, entitled ‘Cyclosporine C2 monitoring for frequent-
relapsing nephrotic syndrome in children: A randomized
controlled trial’ is now being conducted to evaluate the
efficacy and safety of C2 of CyA in children with FRNS.
In conclusion, our results suggest that treatment with CyA
for 2 years in a dosage that maintains the trough level
between 80 and 100 ng/ml for the first 6 months and 60
and 80 ng/ml for the next 18 months is an effective and
relatively safe treatment for children with FRNS. With this
regimen, approximately half of these patients can be expected
not to have relapse during treatment, without the most
critical adverse effect of CyA, that is, interstitial changes
of the kidney. The Sandimmune formulation of CyA was
used in the trial, and Neoral is now being evaluated in a
subsequent trial.
MATERIALS AND METHODS
Patients
Patients with FRNS who were younger than 18 years were eligible for
enrollment. The criteria for and definitions of nephrotic syndrome,
remission, and relapse were in accordance with the International
Study of Kidney Disease in Children.4 FRNS was defined as two or
more relapses of nephrotic syndrome within 6 months of the initial
episode, three or more relapses within any 6-month period, or four
or more relapses within any 12-month period. Exclusion criteria
consisted of the following: previous treatment with CyA, renal
insufficiency (creatinine clearance of p60 ml per min per 1.73 m2),
active infections, secondary nephrotic syndrome, and pregnancy.
The study was performed in accordance with the ethical standards
laid down in the Declaration of Helsinki Principles, and informed
consent was obtained from all patients.
Study design
Patients were assigned to either Group A or B with the use of a
randomization list prepared by the steering committee. The total
duration of treatment was 24 months (Figure 6). For the first
6 months of treatment, both groups received CyA (Sandimmune) in
a dose that maintained the whole-blood trough level between 80 and
100 ng/ml. During months 7–24, Group A received CyA in a dose
producing a whole-blood trough level between 60 and 80 ng/ml
(Regimen A), and Group B received CyA in a fixed dosage of
2.5 mg/kg/day (Regimen B), the dose used in previous study of
children with FRNS10 and approved by the MHLW in Japan. After
2 years of treatment, all patients were scheduled to undergo renal
biopsy, and the dose of CyA was tapered by 0.5–1.0 mg/kg/day
every week. The concomitant use of drugs other than corticosteroids
and immunosuppressants was not restricted. Antihypertensive
drugs, including angiotensin-converting enzyme inhibitors, were
also permitted.
We estimated that a sample size of 90 (Group A, 45 and Group B, 45)
followed for 2 years would permit the detection of a hazard ratio
of 0.46 at a significance level of 0.05 and a power of 0.80. During the
study, a new formulation of CyA, that is, Neoral (Novartis), was
approved by the MHLW, and the steering committee decided to
terminate patient recruitment. A total of 56 patients (Group A, 29
and Group B, 27) gave informed consent and were enrolled.
Corticosteroid treatment for relapses
To treat initial episodes of nephrotic syndrome, patients received
2 mg/kg/day of prednisolone in three divided doses (maximum
dose 80 mg/day) for 4 weeks and were then given a single dose of
1.3 mg/kg of prednisolone in the morning on alternate days for
4 weeks. Patients who had relapses of nephrosis during the study
period received 2 mg/kg/day of prednisolone in three divided doses
(maximum dose 80 mg/day) for 4 weeks, followed by a single dose
of 2 mg/kg of prednisolone administered in the morning on
alternate days for 2 weeks, 1 mg/kg on alternate days for 2 weeks,
and 0.5 mg/kg on alternate days for 2 weeks. No patient received
maintenance therapy with corticosteroids. Patients who had FRNS
during follow-up received off-protocol therapy, left to the discretion
of their physicians.
Pretreatment evaluation and follow-up
The patient’s characteristics (including age, sex, and the results of
blood tests) were first recorded at baseline. Blood analysis (complete
blood cell count, blood chemistry, and CyA trough level) and urine
tests (urinalysis, quantitative proteinuria, and urinary b2-micro-
globulin) were performed monthly for patients in both groups
during follow-up. Abnormal laboratory findings and adverse events
were reported to the steering committee. The trough level of CyA
was measured monthly by monoclonal radioimmunoassay.
Statistical analysis
The primary end point was the proportion of patients who had
sustained remission until the first relapse. The secondary end point
was progression-free survival, using the period until the develop-
ment of FRNS. Survival curves were estimated by the Kaplan–Meier
method and were compared using the log-rank test. Since both
groups received the same treatment regimen for the first 6 months,
the proportion of sustained remission and progression (to FRNS)-
free survival were calculated in patients without relapse or
progression to FRNS for the first 6 months for secondary analysis.
In these analyses, patients without an event were censored at the
date of the last follow-up. The hazard ratio of the relapse rate and
the rate of progression (to FRNS) were estimated by Cox regression
analysis.
A two-sided significance level of 0.05 was used for analysis of the
primary end point. All statistical analyses were performed with the
use of the software package SAS for Windows, release 8.02 (SAS
Institute Inc., Cary, NC, USA).
6 months
Fixed dose of 2.5 mg/kg
24 months
Renal biopsy
CyA trough 
80–100 ng/ml
CyA trough 
80–100 ng/ml
Group A
Group B
Maintenance prednisolone is not prescribed
Random 
allocation
60–80 ng/ml
Figure 6 | Protocol of the trial. CyA, cyclosporine.
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Registration
This study has been registered in a public trials registry, UMIN (the
University Hospital Medical Information Network, ID C000000014,
http://www.umin.ac.jp/ctr/index.htm).
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